Diagnosis and management of hypocalcemia

J Pepe, L Colangelo, F Biamonte, C Sonato… - Endocrine, 2020 - Springer
The aim of this clinical narrative review is to summarize and critically appraise the literature
on the differential diagnosis of hypocalcemia and to provide its correct management …

[HTML][HTML] Bisphosphonates and osteonecrosis of the jaws: Clinical and forensic aspects

D Nogueira, IM Caldas, RJ Dinis-Oliveira - Archives of Oral Biology, 2023 - Elsevier
Objective This manuscript aims to provide a comprehensive review of the current knowledge
in the pathophysiology, diagnosis, prevention, and other relevant forensic and clinical …

Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women—a randomized controlled study

D König, S Oesser, S Scharla, D Zdzieblik, A Gollhofer - Nutrients, 2018 - mdpi.com
Introduction: Investigations in rodents as well as in vitro experiments have suggested an
anabolic influence of specific collagen peptides (SCP) on bone formation and bone mineral …

II Consenso colombiano para el manejo de la osteoporosis posmenopáusica

AM Orjuela, ÓR Olarte, PNR Plata, FS Escobar… - Revista Colombiana de …, 2018 - Elsevier
Resumen La Asociación Colombiana de Osteoporosis y Metabolismo Mineral se reunió a
principios de 2017 para actualizar el Consenso Colombiano de Osteoporosis, elaborado …

Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study

NK Choi, DH Solomon, TN Tsacogianis… - Journal of Bone and …, 2017 - academic.oup.com
Limited head‐to‐head comparative safety and effectiveness data exist between denosumab
and zoledronic acid in real‐world healthcare. We aimed to examine the safety and …

Electrocardiogram Changes Following Intravenous Bisphosphonate Infusion: A Systematic Review and Meta‐Analysis

A Shoung, N Shoung, R Hii, N Nerlekar… - Journal of Bone and …, 2023 - academic.oup.com
Bisphosphonates are first‐line treatments for several bone and mineral disorders. Studies
have reported an increased incidence of serious atrial fibrillation in patients receiving …

The use of bone-modifying agents in multiple myeloma

M Hussain, F Khan, S Al Hadidi - Blood Reviews, 2023 - Elsevier
Multiple myeloma is a hematological neoplasm characterized by abnormal proliferation of
plasma cells in the bone marrow and is usually associated with increased bone pain and …

Hypercalcaemia and hypocalcaemia: finding the balance

JJ Body, D Niepel, G Tonini - Supportive Care in Cancer, 2017 - Springer
Calcium metabolism in cancer and hypercalcaemia of malignancy The balance between
bone formation and resorption may be disrupted in patients with cancer, leading either to …

Side effects of bone-targeted therapies in advanced breast cancer

C Domschke, F Schuetz - Breast Care, 2014 - karger.com
In up to 75% of cases, advanced breast cancer patients eventually develop bone
metastases with often debilitating skeletal-related events (SREs). Osteoclast inhibitors are …

A retrospective analysis of the prevalence and clinical outcomes of vitamin D deficiency in myeloma patients in tropical Australia

K Nath, V Ganeshalingam, B Ewart, E Heyer… - Supportive Care in …, 2020 - Springer
Purpose The aim of this descriptive study was to assess the prevalence of vitamin D
deficiency in patients on active therapy for multiple myeloma in a tropical climate. We also …